Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Patrizia Giannatempo
Based on 1 article published since 2010
(Why 1 article?)

Between 2010 and 2020, Patrizia Giannatempo wrote the following article about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. 2019

Signorelli, Diego / Giannatempo, Patrizia / Grazia, Giulia / Aiello, Marco Maria / Bertolini, Federica / Mirabile, Aurora / Buti, Sebastiano / Vasile, Enrico / Scotti, Vieri / Pisapia, Pasquale / Cona, Maria Silvia / Rolfo, Christian / Malapelle, Umberto / Anonymous6891118. ·Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy. · Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy. · Department of Research, Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy. · Oncology Unit, Policlinico - Vittorio Emanuele Hospital, Via Salvatore Citelli 6, 95124, Catania, Italy. · University Hospital of Modena, Via del Pozzo 71, 41124, Modena, Italy. · Department of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy. · Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy. · Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Pisa, Italy. · Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. · Department of Public Health, University of Naples "Federico II", via Sergio Pansini 5, 80131, Naples, Italy. · Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, 655 W Baltimore S, Baltimore, 21201, Maryland, USA. ·Biomed Res Int · Pubmed #31179334.

ABSTRACT: Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD-L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection.